In contrast, third-generation TKIs, exemplified by osimertinib for EGFR-mutated NSCLC and lorlatinib for ALK-rearranged disease, represent the current benchmark for intracranial disease management [69,70,71]. This evidence concerns the gene ALK and non-small cell lung carcinoma.